Chronic Kidney Disease Management in Primary Care
Primary care management of CKD centers on early identification through targeted screening, aggressive cardiovascular risk reduction with guideline-directed medical therapy (SGLT2 inhibitors, RAS inhibitors, statins), and systematic monitoring to prevent progression and reduce mortality.
Screening and Diagnosis
Screen annually for CKD in high-risk populations—specifically patients with diabetes, hypertension, cardiovascular disease, or family history of kidney disease 1, 2. Do not screen the general population 3.
Essential screening tests include:
- Estimated glomerular filtration rate (eGFR) from serum creatinine
- Urine albumin-to-creatinine ratio (UACR)
- Blood pressure measurement
CKD is defined as eGFR <60 mL/min/1.73 m² and/or markers of kidney damage (albuminuria) persisting for at least 3 months 3. Confirm abnormal results before diagnosing CKD.
Foundational Pharmacotherapy
SGLT2 Inhibitors and RAS Inhibitors: The Core
For patients with CKD (especially with diabetes and albuminuria), initiate an SGLT2 inhibitor alongside a RAS inhibitor (ACE inhibitor or ARB) as foundational therapy 1, 2. This combination prevents CKD progression, reduces cardiovascular events, decreases heart failure hospitalization, and lowers all-cause mortality 4.
The evidence for SGLT2 inhibitors is particularly strong—they provide kidney and cardiovascular protection in patients both with and without type 2 diabetes 4. Despite this, uptake remains slow, particularly in non-diabetic CKD patients, representing a significant gap in care 4.
Adding Nonsteroidal MRAs
For patients with type 2 diabetes and CKD who have persistent albuminuria despite RAS inhibitor and SGLT2 inhibitor therapy, consider adding a nonsteroidal mineralocorticoid receptor antagonist (MRA) like finerenone 1.
Finerenone dosing algorithm:
- If K+ ≤4.8 mmol/L: Start finerenone 10 mg daily (eGFR 25-59) or 20 mg daily (eGFR ≥60)
- If K+ 4.9-5.5 mmol/L: Continue current dose, monitor potassium every 4 months
- If K+ >5.5 mmol/L: Hold finerenone, adjust diet/medications, recheck potassium, restart at 10 mg when K+ ≤5.0 mmol/L
Monitor potassium at 1 month after initiation, then every 4 months. Select patients with consistently normal potassium and avoid in those with baseline hyperkalemia 1.
GLP-1 Receptor Agonists
For patients with type 2 diabetes and CKD not achieving glycemic targets despite metformin and SGLT2 inhibitor use, add a long-acting GLP-1 RA with documented cardiovascular benefits 1.
Blood Pressure Management
Target blood pressure <140/90 mm Hg for all CKD patients 3. Use RAS inhibitors (ACE inhibitors or ARBs) as first-line agents, particularly in patients with albuminuria and hypertension 1, 3.
Lipid Management
Statin Therapy
For adults ≥50 years with eGFR <60 mL/min/1.73 m² (G3a-G5), prescribe a statin or statin/ezetimibe combination 5. This is a strong recommendation (1A evidence).
For adults ≥50 years with eGFR ≥60 (G1-G2), prescribe a statin 5.
For adults 18-49 years with CKD, prescribe a statin if they have:
- Known coronary disease
- Diabetes mellitus
- Prior ischemic stroke
- 10-year cardiovascular risk >10% 5
Choose statin regimens that maximize LDL cholesterol reduction to achieve the largest treatment benefit 5. Consider PCSK-9 inhibitors for patients with appropriate indications 5.
Glycemic Control
For patients with diabetes and CKD, target HbA1c ≤7% 3. Prioritize medications with cardiorenal benefits (SGLT2 inhibitors, GLP-1 RAs) over traditional agents.
Monitoring and Complications Management
Metabolic Acidosis
Consider pharmacological treatment with or without dietary intervention when serum bicarbonate <18 mmol/L in adults 1. Monitor to ensure treatment doesn't cause bicarbonate >upper limit of normal or adversely affect blood pressure, potassium, or fluid status 1.
Hyperkalemia Management
Be aware of potassium measurement variability and factors affecting results (diurnal variation, plasma vs. serum samples, medications) 1. For patients with CKD G3-G5 and history of hyperkalemia, limit intake of foods rich in bioavailable potassium, particularly processed foods 1, 5.
Hyperuricemia and Gout
For CKD patients with symptomatic hyperuricemia (gout), offer uric acid-lowering therapy 1, 5. Prescribe xanthine oxidase inhibitors (not uricosuric agents) 5. For acute gout, use low-dose colchicine or glucocorticoids rather than NSAIDs 5.
Do not use uric acid-lowering agents in asymptomatic hyperuricemia to delay CKD progression 5.
Anemia and Mineral Bone Disorder
Monitor for and manage CKD-associated complications including anemia and mineral bone disorder as eGFR declines 3.
Cardiovascular Disease Management
Antiplatelet Therapy
Prescribe low-dose aspirin for secondary prevention in CKD patients with established ischemic cardiovascular disease 5. Consider P2Y12 inhibitors if aspirin intolerant 5.
Atrial Fibrillation
For thromboprophylaxis in atrial fibrillation with CKD G1-G4, use non-vitamin K antagonist oral anticoagulants (NOACs) rather than warfarin 5. Dose adjustment for eGFR is required, with particular caution at CKD G4-G5 5.
Medication Safety
Adjust medication dosing based on eGFR and avoid nephrotoxins, particularly NSAIDs 3. Review all medications for appropriate dosing and potential kidney toxicity at each visit.
Referral to Nephrology
Refer to nephrology when:
- eGFR <30 mL/min/1.73 m² 3
- Severe albuminuria 3
- Acute kidney injury 3
- Rapid progression of CKD
- Difficulty managing complications 2
Common Pitfalls
The most significant gap in CKD care is clinical inertia—failure to initiate guideline-directed therapy despite clear indications 6. Many patients with moderate to severe CKD remain undiagnosed due to infrequent surveillance of high-risk populations 6.
Avoid these errors:
- Failing to screen high-risk patients annually
- Not confirming abnormal results before diagnosing CKD
- Delaying SGLT2 inhibitor initiation in eligible patients
- Withholding RAS inhibitors due to minor creatinine increases (small rises are expected and acceptable)
- Prescribing NSAIDs in CKD patients
- Missing dose adjustments for renally cleared medications
Patient Education and Multidisciplinary Care
Most patients with early-stage CKD are unaware of their diagnosis 4. Explicitly inform patients of their CKD diagnosis, explain the importance of blood pressure control, medication adherence, and lifestyle modifications (Mediterranean-style diet, sodium restriction, exercise) 5, 4.
Involve dietitians for nutritional counseling, particularly regarding potassium and protein intake in advanced CKD 1. Coordinate care between primary care, nephrology, cardiology, and endocrinology as needed 4, 6.